He Shikun, Ouyang Sha, Li Xiaohua, Ma Binyun
Department of Pathology and USC Roski Eye Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA.
Department of Ophthalmology, the Third Xiangya Hospital, Central South University, Changsha, China.
Ann Transl Med. 2021 Jan;9(1):18. doi: 10.21037/atm-20-3810.
Choroidal neovascularization (CNV) is a leading cause of central vision loss complicated with age-related macular degeneration. Although intravitreal anti-VEGF therapy is widely used in wet age-related macular degeneration, optimal treatment regimens for the disease are still under investigation. EphrinB2 and EphB4 regulate angiogenesis, and interruption of EphB4/ephrinB2 has been demonstrated to inhibit angiogenesis. In the current study, we studied the effects of soluble EphB4 (sEphB4) on laser induced CNV in a rat model by intravitreous injection and the underlying mechanism.
Male rats (Brown-Norway) were used in the study. CNV was induced by laser and the sEphB4 was injected intravitreous after laser at days 3 and 7. The CNV lesions were evaluated by three methods: fluorescein angiography (FA) , CNV volume by confocal analysis of choroidal flat-mounts and H&E staining. The expression of fibronectin (FN), VEGFR-2, phospho-VEGFR-2 (pVEGFR-2), the double labeling of EphB4 with FN was analyzed by immunofluorescence. The interaction of FN with EphB4 and the effects of intraocular injection of sEphB4 on the inhibition of pVEGFR-2 were determined by western blot.
The FA leakage and CNV volume were significantly inhibited by the injection of the sEphB4. Further, histology analysis showed that CNV lesion was significantly smaller in the rats with sEphB4 injection than rats with placebo application. The expressions of pVEGFR-2 and FN in the CNV lesions were reduced compared with controls.
Our study suggests that the inhibition of CNV by sEphB4 may be through suppression of VEGFR-2 phosphorylation and the expression of FN. sEphB4 may be a new potential therapeutic strategy of CNV.
脉络膜新生血管(CNV)是导致年龄相关性黄斑变性伴发中心视力丧失的主要原因。尽管玻璃体内抗血管内皮生长因子(VEGF)治疗广泛应用于湿性年龄相关性黄斑变性,但该病的最佳治疗方案仍在研究中。EphrinB2和EphB4调节血管生成,并且已证实阻断EphB4/ephrinB2可抑制血管生成。在本研究中,我们通过玻璃体内注射研究了可溶性EphB4(sEphB4)对大鼠模型中激光诱导的CNV的影响及其潜在机制。
本研究使用雄性大鼠(布朗-挪威大鼠)。通过激光诱导CNV,并在激光照射后第3天和第7天玻璃体内注射sEphB4。通过三种方法评估CNV病变:荧光素血管造影(FA)、脉络膜平铺共聚焦分析的CNV体积以及苏木精-伊红(H&E)染色。通过免疫荧光分析纤连蛋白(FN)、血管内皮生长因子受体2(VEGFR-2)、磷酸化血管内皮生长因子受体2(pVEGFR-2)的表达,以及EphB4与FN的双重标记。通过蛋白质印迹法测定FN与EphB4的相互作用以及玻璃体内注射sEphB4对pVEGFR-2抑制的影响。
注射sEphB4可显著抑制FA渗漏和CNV体积。此外,组织学分析表明注射sEphB4的大鼠的CNV病变明显小于应用安慰剂的大鼠。与对照组相比,CNV病变中pVEGFR-2和FN的表达降低。
我们的研究表明,sEphB4对CNV的抑制作用可能是通过抑制VEGFR-2磷酸化和FN的表达实现的。sEphB4可能是一种新的潜在CNV治疗策略。